{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+80%25", "query": { "intervention": "Glargine 80%" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+80%25&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T23:29:05.361Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01676220", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 117, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676220" }, { "nct_id": "NCT00993473", "title": "6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Neutral Protamine Hagedorn (NPH) insulin", "type": "DRUG" }, { "name": "Insulin lispro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "6 Years", "sex": "ALL", "summary": "1 Year to 6 Years" }, "enrollment_count": 125, "start_date": "2009-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-06-27", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 8, "location_summary": "Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00993473" }, { "nct_id": "NCT03336528", "title": "Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Degludec", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2018-01-02", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Spokane, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336528" }, { "nct_id": "NCT03211858", "title": "Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin aspart", "type": "DRUG" }, { "name": "NovoLog/NovoRapid", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 597, "start_date": "2017-08-02", "completion_date": "2019-01-12", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 42, "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 35 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211858" }, { "nct_id": "NCT02738151", "title": "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300U/mL", "type": "DRUG" }, { "name": "Insulin degludec, 100 U/mL", "type": "DRUG" }, { "name": "Non-insulin anti-diabetic treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 929, "start_date": "2016-05-19", "completion_date": "2017-08-15", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 74, "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02738151" }, { "nct_id": "NCT03908762", "title": "mHealth Titration and Management", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2", "Diabetic Complication" ], "interventions": [ { "name": "iSage App with connected glucometer", "type": "DEVICE" }, { "name": "Magnet", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "Amalgam Rx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "21 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2019-01-01", "completion_date": "2020-03", "has_results": false, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03908762" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT01768559", "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Insulin glulisine QD", "type": "DRUG" }, { "name": "Insulin glulisine TID", "type": "DRUG" }, { "name": "Insulin Glargine (Mandatory background drug)", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 894, "start_date": "2013-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 46, "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768559" }, { "nct_id": "NCT02455076", "title": "Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Rapid-acting insulin analogs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 150, "start_date": "2015-09", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2019-06-20", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455076" }, { "nct_id": "NCT02273180", "title": "Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "SAR342434", "type": "DRUG" }, { "name": "Humalog", "type": "DRUG" }, { "name": "Insulin glargine HOE901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 507, "start_date": "2014-10", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-01-18", "last_synced_at": "2026-09-23T23:29:05.361Z", "location_count": 47, "location_summary": "Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273180" } ] }